Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$84.21
+0.1%
$79.85
$73.31
$128.73
$211.44B0.3915.77 million shs624,909 shs
Pfizer Inc. stock logo
PFE
Pfizer
$24.73
-0.8%
$24.26
$20.92
$31.54
$140.57B0.5845.22 million shs3.67 million shs
Seagen Inc. stock logo
SGEN
Seagen
$228.74
$228.74
$123.77
$228.96
$42.93B0.321.48 million shs86 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
+0.32%+3.23%+4.79%+1.68%-33.12%
Pfizer Inc. stock logo
PFE
Pfizer
+0.19%+3.17%+4.39%+10.56%-15.38%
Seagen Inc. stock logo
SGEN
Seagen
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
4.9962 of 5 stars
3.24.05.04.24.02.53.8
Pfizer Inc. stock logo
PFE
Pfizer
4.9771 of 5 stars
3.23.04.24.54.01.73.1
Seagen Inc. stock logo
SGEN
Seagen
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.43
Hold$108.6929.07% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.45
Hold$28.5515.47% Upside
Seagen Inc. stock logo
SGEN
Seagen
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest PFE, SGEN, and MRK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/10/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$99.00 ➝ $98.00
5/29/2025
Pfizer Inc. stock logo
PFE
Pfizer
Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold$28.00 ➝ $25.00
5/21/2025
Pfizer Inc. stock logo
PFE
Pfizer
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy$32.00 ➝ $33.00
5/20/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Cautious
5/19/2025
Pfizer Inc. stock logo
PFE
Pfizer
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy$27.00 ➝ $26.00
5/14/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$115.00 ➝ $84.00
4/30/2025
Pfizer Inc. stock logo
PFE
Pfizer
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetUnderperform$22.00 ➝ $23.00
4/30/2025
Pfizer Inc. stock logo
PFE
Pfizer
Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral$29.00 ➝ $27.00
4/30/2025
Pfizer Inc. stock logo
PFE
Pfizer
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral$26.00 ➝ $27.00
4/30/2025
Pfizer Inc. stock logo
PFE
Pfizer
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Perform$28.00 ➝ $26.00
4/30/2025
Pfizer Inc. stock logo
PFE
Pfizer
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral$23.00 ➝ $25.00
(Data available from 7/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$63.92B3.31$9.49 per share8.87$18.33 per share4.59
Pfizer Inc. stock logo
PFE
Pfizer
$63.63B2.21$4.26 per share5.81$15.62 per share1.58
Seagen Inc. stock logo
SGEN
Seagen
$2.30B18.66N/AN/A$15.10 per share15.15
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$17.12B$6.8712.268.510.8827.27%43.23%17.11%7/29/2025 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$8.03B$1.3817.928.160.9212.62%20.33%8.53%8/5/2025 (Estimated)
Seagen Inc. stock logo
SGEN
Seagen
-$610.31M-$4.01N/AN/AN/A-32.61%-28.06%-20.92%N/A

Latest PFE, SGEN, and MRK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Pfizer Inc. stock logo
PFE
Pfizer
$0.57N/AN/AN/A$13.43 billionN/A
7/29/2025Q2 2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$2.03N/AN/AN/A$15.92 billionN/A
4/29/2025Q1 2025
Pfizer Inc. stock logo
PFE
Pfizer
$0.67$0.92+$0.25$0.52$14.43 billion$13.72 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.243.85%N/A47.16%14 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.96%N/A124.64%16 Years
Seagen Inc. stock logo
SGEN
Seagen
N/AN/AN/AN/AN/A

Latest PFE, SGEN, and MRK Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/22/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.813.97%9/15/20259/15/202510/7/2025
6/25/2025
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.437.08%7/25/20257/25/20259/2/2025
5/27/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.814.18%6/16/20256/16/20257/8/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.69
1.41
1.16
Pfizer Inc. stock logo
PFE
Pfizer
0.64
1.26
0.96
Seagen Inc. stock logo
SGEN
Seagen
N/A
2.67
2.12

Institutional Ownership

CompanyInstitutional Ownership
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
Seagen Inc. stock logo
SGEN
Seagen
84.26%

Insider Ownership

CompanyInsider Ownership
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.13%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%
Seagen Inc. stock logo
SGEN
Seagen
25.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
75,0002.51 billion2.51 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
81,0005.69 billion5.68 billionOptionable
Seagen Inc. stock logo
SGEN
Seagen
3,256187.70 million139.08 millionOptionable

Recent News About These Companies

Merck in "advanced talks" for $40bn Seagen bid; report
Seagen posts breast cancer win ahead of Pfizer takeover
Is Merck planning a $30bn-plus move for Seagen?
Pfizer raises guidance as COVID franchise drives Q3 beat
Franklin Biotechnology Discovery C
Seagen wins Enhertu patent dispute with Daiichi Sankyo
Pfizer: Turning The Corner (Rating Upgrade)
HER2 heats up as Seagen licenses RemeGen ADC for $2.6bn
MRNA Feb 2024 64.000 put
MRNA Feb 2024 77.000 call
MRNA Feb 2024 67.000 put

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$84.21 +0.10 (+0.11%)
As of 10:13 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Pfizer stock logo

Pfizer NYSE:PFE

$24.72 -0.20 (-0.78%)
As of 10:13 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Seagen stock logo

Seagen NASDAQ:SGEN

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.